Final analysis of Covaxin efficacy out; vaccine 65.2 percent effective against Delta variant

Bharat Biotech's Covaxin has demonstrated 77.8 percent effectiveness against symptomatic COVID-19 and 65.2 percent protection against the new Delta variant. The company on Saturday said it concluded the final analysis of Covaxin efficacy from Phase-3 trials. The efficacy analysis demonstrates Covaxin to be 93.4 percent effective against severe symptomatic COVID-19 cases, while safety analysis shows adverse events reported were similar…
« Previous post: | Next post: »